|Bid||14.40 x 1300|
|Ask||14.73 x 800|
|Day's Range||14.60 - 14.73|
|52 Week Range||13.17 - 17.43|
|Beta (5Y Monthly)||1.00|
|PE Ratio (TTM)||11.31|
|Forward Dividend & Yield||0.80 (5.60%)|
|Ex-Dividend Date||Sep 29, 2021|
|1y Target Est||17.76|
The Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more.
Japan's Takeda Pharmaceutical Co said on Wednesday its 12-month operating profit slid 9.5%, although the country's largest drugmaker forecast a rebound for the current year. Chief Executive Christophe Weber said that core operating profit, which strips out impairments and other non-recurring items, would likely exceed 1 trillion yen this fiscal year, and the company's financials would become clearer now that its 2019 absorption of Shire Plc is complete. Takeda is domestically producing the COVID-19 vaccine, developed by Novavax Inc, which was approved by Japanese regulators last month.
OSAKA, Japan, May 11, 2022--Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for fiscal year 2021 (period ended March 31, 2022), driven by the performance of its growth products, new product launches and strength across its key business areas.